Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren + amlodipine versus amlodipine in moderate to severe hypertension
2008-005216-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Aliskiren + amlodipine with Amlodipine monotherapy (2 arms). Primary endpoint: Change from baseline in mean sitting diastolic blood pressure at 8 weeks. Started Oct 2008; status: completed.
02
Drugs
aliskirenamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-005216-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005216-40.